20 / 21
Page 50
December 06-07 , 2018
Amsterdam, Nether l ands
Journal of Neuropsychiatry
ISSN: 2471-8548
Alzheimer’s and Dementia 2018
1 3
t h
W o r l d c o n g r e s s o n
Alzheimer’s and Dementia
C
onverging evidence suggests that the pathophysiology of neurodegenerative diseases (NDDs) begin years, if not decades, prior
to the onset of clinical symptoms, including memory impairment, motor disturbances and non-motor related abnormalities.
Therefore, individuals at very early stages are the most likely to benefit from disease-modifying therapies should they become
available. Currently, NDDs are viewed as multi-etiological disorders with a concomitant occurrence of several pathogenic
mechanisms and thus, the challenge is to find the meaningful biological targets for a rapid translation of knowledge into clinical
drug development. In addition, significant efforts are put in the development of novel drugs to address symptomatology with
compounds directed towards biochemical systems that not necessarily constitute the underlying pathology of the disease in
question but might contribute to a significant relief in patient’s quality of life. In my talk, I will elaborate on strategic pre-clinical
steps and major considerations in drug design intended to accelerate the drug candidate development process. Also, which
pre-requisites a candidate must fulfil in the path to IND-enabling studies to reduce the time and risk of Alzheimer’s disease drug
development. I will provide examples of molecules which do or do not meet industry criteria such as compounds with insufficient
PK characterization, small molecules that generates a toxicchemically reactive metabolite in vivo, insufficient potency, selectivity
or efficacy, poor target engagement, model predictability etc. and a priori comprehension of these essentials will help the
translation into clinic more efficient and reliable.
smandel333@gmail.comAdvancing drug development in Alzheimer’s disease
Silvia A Mandel
1,2
1
Galilee Faculty of Medicine-teva Pharmaceuticals Industries Ltd., Israel
2
Technion Israel institute of Technology, Israel
J Neurol Neurosci 2018, Volume: 2
DOI: 10.21767/2471-8548-C1-003